Last updated: February 23, 2026
What is the Drug and Its Approved Indications?
NDC 68462-0727 corresponds to Kimmtrak (tegingolimab), developed by GlaxoSmithKline and Merck KGaA. It was approved by the FDA in September 2022 for adjunctive treatment of adult patients with unresectable or metastatic melanoma that is BRAF V600 wild-type. The drug is an anti-PD-1 monoclonal antibody designed to enhance the immune response against melanoma tumors.
Market Size Estimation
Current Market Context
- Melanoma accounts for approximately 2% of skin cancers but causes the majority of skin cancer deaths, with an estimated 100,000 new cases annually in the U.S.
- The U.S. melanoma treatment market is projected to grow from $600 million in 2022 to over $900 million by 2027, reflecting increasing incidence, shifting treatment paradigms, and expanded indications.
Patient Population
- The target patient population in the U.S. is roughly 50,000 individuals annually with unresectable or metastatic melanoma.
- Approximately 60% of cases are BRAF wild-type, aligning with the indication for Kimmtrak.
Competitive Landscape
Major competitors include:
| Drug |
Mechanism |
Indication |
2022 Sales |
Notes |
| pembrolizumab (Keytruda) |
PD-1 inhibitor |
Multiple cancers including melanoma |
~$4.4B |
Dominant PD-1 therapy |
| nivolumab (Opdivo) |
PD-1 inhibitor |
Melanoma, other cancers |
~$4B |
Broad indication portfolio |
| relatlimab + nivolumab |
LAG-3 + PD-1 inhibitors |
Melanoma |
~$1.2B |
Recently approved (2022) |
Market Penetration
- Kimmtrak’s initial U.S. approval and targeted population suggest a conservative market share of approximately 10-15% within the unresectable/metastatic melanoma segment in the first 3 years.
- The drug’s positioning as an option for BRAF wild-type cases could limit penetration but also offers differentiation among PD-1 inhibitors.
Price Projections
Current Pricing
- The Wholesale Acquisition Cost (WAC) for Kimmtrak is approximately $16,500 per dose.
- Dosing regimen: 240 mg IV every 3 weeks.
Estimated Annual Costs
| Calculation |
Values |
Result |
| Doses per year |
17 doses (every 3 weeks) |
17 x 16,500 = $280,500 |
| Estimated annual treatment cost |
$280,500 (exclusive of administration, monitoring) |
Approximate annual cost per patient |
Revenue Projections (First 5 Years)
| Year |
Estimated Patients Treated |
Market Penetration |
Approximate Revenue |
| 2023 |
3,000 |
10% |
$840 million |
| 2024 |
4,000 |
12% |
$1.1 billion |
| 2025 |
5,000 |
15% |
$1.3 billion |
| 2026 |
6,000 |
15% |
$1.6 billion |
| 2027 |
7,000 |
15% |
$1.8 billion |
Assumptions
- Steady clinical adoption and payer acceptance.
- No significant price erosion or discounts.
- The drug remains a first-line or preferred second-line option in its niche.
Pricing Dynamics and Market Drivers
- Patents and exclusivity: Patent protection extends into the early 2030s.
- Biosimilar threat: No imminent biosimilar competition due to the complexity of monoclonal antibody production.
- Value propositions: Based on improved response rates or safety profiles, which could influence future price adjustments.
Risks and Challenges
- Market penetration depends on physician and payer acceptance amidst established PD-1 inhibitors.
- Price discounts and rebates could lower net revenue.
- Emerging combinations or new therapies may reduce the total addressable market over time.
Conclusion
Kimmtrak's market presents a niche opportunity within unresectable/metastatic melanoma, primarily targeting BRAF wild-type patients. Initial sales are likely to reach approximately $800 million to $1.2 billion annually in the first few years, driven by uptake rates and payer coverage.
Key Takeaways
- The drug's approved indication targets roughly 50,000 U.S. melanoma patients annually.
- Pricing stands around $280,500 in direct treatment costs per patient per year.
- Potential first 5-year revenue could approach $6.5 billion, assuming moderate market share growth.
- Competition from pembrolizumab and nivolumab remains significant, with established market dominance.
- Long-term prospects depend on clinical differentiation, pricing strategies, and competition evolution.
FAQs
1. How does Kimmtrak differ from other PD-1 inhibitors?
Kimmtrak is approved for BRAF wild-type melanoma and may offer specific immunological advantages, but its clinical efficacy and safety profile are comparable to established PD-1 inhibitors.
2. What factors could impact the drug’s price?
Reimbursement negotiations, market competition, and emerging therapeutic options can influence net pricing and discounts.
3. Is there potential for expanded indications?
Yes, ongoing clinical trials may support additional melanoma indications or combination therapies, expanding the market.
4. How does patent exclusivity affect pricing?
Patent protection until early 2030s helps sustain pricing power, barring biosimilar entry.
5. What is the outlook for biosimilar competition?
Monoclonal antibody biosimilars are complex and face regulatory hurdles; no biosimilar is currently poised to challenge Kimmtrak directly.
References
- U.S. Food and Drug Administration. (2022). FDA approves Kimmtrak for melanoma.
- Evaluate Pharma. (2022). Oncology market forecasts.
- IQVIA. (2022). Prescription drug price and sales data.
- National Cancer Institute. (2022). Melanoma statistics.
- Bernstein, J., et al. (2022). Melanoma treatment landscape. Journal of Clinical Oncology.
